Keytruda bonanza inspires a facelift and plans to invest more than $600M in translational research
Scientists with the UK’s MRC Technology played a key role in humanizing the antibody that would go on to become Keytruda, Merck’s new flagship checkpoint …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
